Fig. 5

DBP predicts HCI-010 and HCI-025 treatment responses. HCI-010 (a) or HCI-025 (b) PDX-derived tumor cells were treated with vehicles, ABT-263, ABBV-321, ABT-263+ABBV-321, AB095-PBD, or ABT-263+AB095-PBD. The graphs present delta (Δ) priming as a normalized percentage (%) value for PDX-derived tumor cells (n = 3 tumors per PDX) evaluated in one of three independent DBP experiments. Each symbol represents PDX-derived cells evaluated once or twice per experiment. Each bar represents the mean. For HCI-010 (a), note that priming was observed under ABT-263 treatment and enhanced priming was observed under ABT-263+ABBV-321 combined treatments, consistent with the in vivo responses observed in Fig. 4. For HCI-010 (a), also note that insignificant priming was observed under either AB095-PBD or ABT-263+AB095-PBD treatment conditions. p values > 0.05 = NS are indicated for the most relevant comparisons (Welch’s one-tailed test: vehicles versus AB095-PBD and ABT-263 versus ABT-263+AB095-PBD). For HCI-025 (b), note that priming was observed under ABBV-321 treatment and enhanced priming following combined treatment with ABT-263, consistent with the in vivo responses observed in Fig. 4. For HCI-025 (b), also note that insignificant priming was observed under either AB095-PBD or ABT-263+AB095-PBD treatment conditions. p values > 0.05 = NS are indicated for the most relevant comparisons (Welch’s one-tailed test: vehicles versus AB095-PBD and vehicles versus ABT-263+AB095-PBD). p values, determined by Welch’s one-tailed test, for additional HCI-010 and HCI-025 comparisons are presented in Supplemental Table 2d